Amylin Acquisition is a Mild Positive for Bristol-Myers Squibb
I prefer growth through internal product development over growth through acquisition. It is the product pipeline that drives my buy recommendation on Bristol-Myers Squibb (BMY). The acquisition of Amylin (AMLN) has some tactical appeal as it strengthens BMY’s position in the diabetes market, is only modestly dilutive in the near term and could be quite accretive in the years beyond 2014. I see it as a modest positive. For more detail follow this link to the company reports section of my website.
Tagged as Amylin acquisition, Bristol-Myers Squibb + Categorized as Company Commentary